Versant Capital Management’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-11
| Closed | -$115 | – | 2701 |
|
|
2025
Q1 | $115 | Hold |
11
| – | – | ﹤0.01% | 2484 |
|
|
2024
Q4 | $157 | Hold |
11
| – | – | ﹤0.01% | 2342 |
|
|
2024
Q3 | $220 | Hold |
11
| – | – | ﹤0.01% | 1956 |
|
|
2024
Q2 | $210 | Hold |
11
| – | – | ﹤0.01% | 1900 |
|
|
2024
Q1 | $158 | Hold |
11
| – | – | ﹤0.01% | 1846 |
|
|
2023
Q4 | $95 | Sell |
11
-39
| -78% | -$295 | ﹤0.01% | 1898 |
|
|
2023
Q3 | $448 | Hold |
50
| – | – | ﹤0.01% | 1713 |
|
|
2023
Q2 | $433 | Hold |
50
| – | – | ﹤0.01% | 1864 |
|
|
2023
Q1 | $478 | Sell |
50
-148
| -75% | -$4.48K | ﹤0.01% | 1588 |
|
|
2022
Q4 | $6.7K | Buy |
198
+121
| +157% | +$5.86K | ﹤0.01% | 793 |
|
|
2022
Q3 | $4K | Buy |
77
+28
| +57% | +$1.67K | ﹤0.01% | 912 |
|
|
2022
Q2 | $3K | Buy |
49
+13
| +36% | +$820 | ﹤0.01% | 1009 |
|
|
2022
Q1 | $3K | Buy |
36
+35
| +3,500% | +$5.18K | ﹤0.01% | 1049 |
|
|
2021
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 1539 |
|
|
2021
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 1544 |
|
|
2021
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 1548 |
|
|
2021
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 1574 |
|
|
2020
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 1467 |
|
|
2020
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 1433 |
|
|
2020
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 1470 |
|
|
2020
Q1 | $0 | Sell |
1
-2
| -67% | -$619 | ﹤0.01% | 1554 |
|
|
2019
Q4 | $1K | Hold |
3
| – | – | ﹤0.01% | 1252 |
|
|
2019
Q3 | $0 | Sell |
3
-2
| -40% | -$733 | ﹤0.01% | 1518 |
|
|
2019
Q2 | $2K | Sell |
5
-11
| -69% | -$5.52K | ﹤0.01% | 1194 |
|
|
2019
Q1 | $8K | Sell |
16
-48
| -75% | -$28.4K | ﹤0.01% | 985 |
|
|
2018
Q4 | $31K | Sell |
64
-6
| -9% | -$3.62K | 0.01% | 372 |
|
|
2018
Q3 | $63K | Sell |
70
-58
| -45% | -$49.5K | 0.03% | 234 |
|
|
2018
Q2 | $93K | Sell |
128
-12
| -9% | -$13.8K | 0.04% | 162 |
|
|
2018
Q1 | $223K | Sell |
140
-16
| -10% | -$20.6K | 0.09% | 94 |
|
|
2017
Q4 | $139K | Buy |
156
+21
| +16% | +$12.4K | 0.06% | 121 |
|
|
2017
Q3 | $48K | Buy |
135
+58
| +75% | +$18.1K | 0.03% | 265 |
|
|
2017
Q2 | $22K | Buy |
77
+29
| +60% | +$8.38K | 0.01% | 558 |
|
|
2017
Q1 | $16K | Buy |
48
+47
| +4,700% | +$10.6K | 0.01% | 666 |
|
|
2016
Q4 | $0 | Sell |
1
-3
| -75% | -$610 | ﹤0.01% | 1480 |
|
|
2016
Q3 | $0 | Hold |
4
| – | – | ﹤0.01% | 1451 |
|
|
2016
Q2 | $0 | Hold |
4
| – | – | ﹤0.01% | 1406 |
|
|
2016
Q1 | $0 | Hold |
4
| – | – | ﹤0.01% | 1412 |
|
|
2015
Q4 | $0 | Buy |
+4
| New | +$823 | ﹤0.01% | 1399 |
|
Other funds holding NKTR
NCM
TCM
Versant Capital Management's NKTR Position: Q2 2025 in Review
Versant Capital Management sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 11 shares — an estimated $115 sold.
Versant Capital Management first reported a position in NKTR in Q4 2015 and held it in 38 quarters. The position peaked at $223K in Q1 2018. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.
- Versant Capital Management reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
- Versant Capital Management sold 11 Nektar Therapeutics shares in Q2 2025, an estimated $115.
- Versant Capital Management first reported a position in Nektar Therapeutics in Q4 2015 and held it in 38 quarters.
- Versant Capital Management's Nektar Therapeutics position peaked at $223K in Q1 2018.
- 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.
Based on Versant Capital Management's 13F filing for Q2 2025, filed 7 Jul 2025.